​

NeuroSense Therapeutics Ownership | Who Owns NeuroSense Therapeutics?

OverviewChart

NeuroSense Therapeutics Ownership Summary

NeuroSense Therapeutics is owned by 2.08% institutional investors, 29.68% insiders, and 68.25% retail investors. Meitav investment house is the largest institutional shareholder, holding 0.16% of NRSN shares. Fidelity Nasdaq Composite Index is the top mutual fund, with 0.06% of its assets in NeuroSense Therapeutics shares.

NRSN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockNeuroSense Therapeutics2.08%29.68%68.25%
SectorHealthcare Stocks 492.67%11.09%-403.76%
IndustryBiotech Stocks 295.31%11.22%-206.53%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Meitav investment house40.00K0.16%$50.00K
Hrt financial lp21.69K0.10%$41.00K
Commonwealth equity services21.08K0.08%$26.00K
Geode capital management15.87K0.06%$19.84K
Ubs group14.66K0.06%$18.32K
Morgan stanley1.50K0.01%$1.68K
Sbi securities1.46K0.01%$1.82K
Cwm1.00K0.00%$1.00K
Jones financial companies lllp1.00K0.00%$1.24K
Cantor fitzgerald, l. p.---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Meitav investment house40.00K0.00%$50.00K
Hrt financial lp21.69K0.00%$41.00K
Commonwealth equity services21.08K-$26.00K
Marshall wace, llp---
Two sigma securities---
Cwm1.00K-$1.00K
Renaissance---
Jane street group---
Cantor fitzgerald, l. p.---
Geode capital management15.87K-$19.84K

Top Buyers

HolderShares% AssetsChange
Hrt financial lp21.69K0.00%21.69K
Ubs group14.66K-13.05K
Meitav investment house40.00K0.00%-
Commonwealth equity services21.08K--
Geode capital management15.87K--

Top Sellers

HolderShares% AssetsChange
Armistice capital---1.58M
Cantor fitzgerald, l. p.---79.49K
Renaissance---71.10K
Xtx topco---33.71K
Jane street group---28.69K

Sold Out

HolderChange
Qube research-54.00
Total investment management-500.00
Hurley capital-6.53K
Bnp paribas arbitrage, snc-6.80K
Warberg asset management-10.70K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20251536.36%449,544130.66%2294.96%10233.33%2-33.33%
Mar 31, 202511-15.38%194,892-69.85%-6.54%3-70.00%3200.00%
Dec 31, 20241385.71%646,513186.89%3229.84%10150.00%1-
Sep 30, 20247-225,356-86.52%11.06%4100.00%--100.00%
Jun 30, 20247-12.50%1,671,167899.94%10918.60%2-33.33%1-

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Nasdaq Composite Index15.87K0.06%-

NRSN Ownership FAQ

Who Owns NeuroSense Therapeutics?

NeuroSense Therapeutics shareholders are primarily institutional investors at 2.08%, followed by 29.68% insiders and 68.24% retail investors. The average institutional ownership in NeuroSense Therapeutics's industry, Biotech Stocks , is 295.31%, which NeuroSense Therapeutics falls below.

Who owns the most shares of NeuroSense Therapeutics?

NeuroSense Therapeutics’s largest shareholders are Meitav investment house (40K shares, 0.16%), Hrt financial lp (21.69K shares, 0.10%), and Commonwealth equity services (21.08K shares, 0.08%). Together, they hold 0.34% of NeuroSense Therapeutics’s total shares outstanding.

Does Blackrock own NeuroSense Therapeutics?

BlackRock is not among the top 10 institutional shareholders of NeuroSense Therapeutics.

Who is NeuroSense Therapeutics’s biggest shareholder by percentage of total assets invested?

Meitav investment house is NeuroSense Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.00% of its assets in 40K NeuroSense Therapeutics shares, valued at 50K$.

Who is the top mutual fund holder of NeuroSense Therapeutics shares?

Fidelity Nasdaq Composite Index is the top mutual fund holder of NeuroSense Therapeutics shares, with 0.06% of its total shares outstanding invested in 15.87K NeuroSense Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools